PATENT CLAIM ANALYSIS

Application Number: 15768257
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-11
Patent Classification: ["514", "234200"]

Abstract:
The invention provides a method of inhibiting casein kinase 1δ (CK1δ), comprising contacting the CK1δ with a compound of formula (I), as defined herein; such as compound SR-3029. We demonstrate that CSNK1D is amplified and/or overexpressed in human breast tumors and that CK1δ can be medically targeted in human breast cancer subtypes overexpressing this kinase. The invention further provides a method of treating cancer, such as a breast cancer, melanoma, glioblastoma, medulloblastoma, renal, bladder or colon cancer, or a cancer that metastasizes to the brain, lung, or bone provided that both elevated CK1δ and β-catenin dependence are involved in those metastatic diseases. The cancer can be a breast cancer of the triple negative subclass of breast cancers (TNBC), or can be an HER+ breast cancer.

Claim (Index 6):
The method of  claim 4 , wherein the breast cancer is of the triple negative subclass of breast cancers (TNBC) or is an HER+ breast cancer.

Metadata:
- Claim Count in Document: 3.0
- Percentile: 91.0
- Lexical Diversity: 1.85
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14798208', '14293632', '15708872', '15371104', '13789005']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7810209677704368
- 35 USC 102 Novelty (BERT): 0.5264361823113318
- Combined Prediction Score: 0.7555624892245263
- Mean Citation Score: 326.9511980000001
- Max Citation Score: 334.1403
- Similarity Product: 230.039121456492

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test